Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec

Revenues up 32% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec
 
3Q Revenues: $1.8 billion (+32%)

3Q Earnings: $488 million (+22%)

YTD Revenues: $5.0 billion (+21%)

YTD Earnings: $1.4 billion (+29%)

Comments: Growth was driven by Tysabri and new MS therapy Tecfidera, with revenues totaling $286 million in the quarter. Avonex sales were flat at $733 million. Tysabri revenues increased 46% to $401 million as a result of gaining full rights from Elan in 2Q13. Rituxan revenues from an unconsolidated joint business arrangement were $303 million in the quarter, up 5%. Royalty revenues totaled $54 million, up 15%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters